For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.
SIMS21, Poland 2017 - Tae Geol Lee abstract

Tae Geol Lee oral presentation (OB4-Thu4-1-4)

High-throughput Drug Screening by ToF-SIMS Imaging Technique

Tae Geol Lee1, Young-Lai Cho1, Young-Pil Kim2, Jin Gyeong Son1, Miyoung Son1

1 KRISS - KRISS, 1 Doryong-dong, Yuseong-gu, 34113 Daejeon, Korea, Republic of
2 Department of Life Science - Hanyang University, 222, Wangsimni-ro, Seongdong-gu, 04763 Seoul, Korea, Republic of


Protein kinases are enzymes that are important targets for drug discovery because of their involvement in regulating the essential cellular processes. For this reason, the changes in protein kinase activity induced by each drug candidate (the inhibitor in this case) need to be accurately determined.

Here, an on-chip secondary ion mass spectrometry (SIMS) imaging technique of the peptides was developed for determining protein kinase activity and inhibitor screening without a matrix. In our method, cysteine-tethered peptides adsorbed onto a gold surface produced changes in the relative peak intensities of the phosphorylated and unphosphorylated substrate peptides, which were quantitatively dependent on protein kinase activity. Using mass spectrometry imaging of multiple compartments on the gold surface in the presence of a peptide substrate, we screened 13,727 inhibitors, of which seven were initially found to have inhibitor efficiencies that surpassed 50%. Of these, we were able to identify a new breakpoint cluster region-abelson (BCR-ABL)T315I kinase inhibitor, henceforth referred to as KR135861. KR135861 showed no cytotoxicity and was subsequently confirmed to be superior to imatinib, a commercial drug marketed as Gleevec. Moreover, KR135861 exhibited a greater inhibitory effect on the BCR-ABLT315I tyrosine kinase, with an IC50 value as low as 1.3 μM. In in vitro experiments, KR135861 reduced the viability of both Ba/F3 cells expressing wild-type BCR-ABL and BCR-ABLT315I, in contrast to imatinib’s inhibitory effects only on Ba/F3 cells expressing wild-type BCR-ABL.

Due to the surface sensitivity and selectivity of SIMS imaging, it is anticipated that our approach will make it easier to validate the small modifications of a substrate in relation to enzyme activity as well as for drug discovery. This mass spectrometry imaging analysis enables efficient screening for protein kinase inhibitors, thus permitting high-throughput drug screening with high accuracy, sensitivity, and specificity [1].

[1] Y.-L. Cho, Y.-P. Kim, J.G. Son, M. Son, T.G. Lee, Analytical Chemistry, 89, 2017, 799-806.